past events
- 2025-
- The 2025 ASA-NJ chapter/Bayer Annual Joint Workshop
- Advancing Evidence Generation in Biomedical Research Using Natural Hermite and Propensity Score Indices: Applications to External Control Arms
- Using Surrogate Endpoints and Win Statistic to Improve Decision-making in Oncology
- Improving Operational Efficiency in Clinical Development through Statistical Innovation and Cross-functional Collaboration
- A Comprehensive Bayesian Decision-Making Framework for Drug Development
- ASA NJ and PT Chapters Spring Symposium 2025
- Practical Difficulties Faced by DMC/DSMB Members in Interim Monitoring of Industry-Sponsored Trials
- Adaptive Pivotal Trial Designs using Multiple Hierarchical Endpoints (FS Statistics and Win ratio): A Practical Example
- Multiplicity Control in Oncology Clinical Trials with a Surrogate Endpoint-Based Drop-The-Losers Design
- Bayesian Interim Analysis and Sample Size Re-estimation of Clinical Trials
- Navigating Complexity: Joint Modeling of Multiple Longitudinal Endpoints and Simulation-Guided Adaptive Designs in Clinical Trials
- The 2025 ASA-NJ chapter/Bayer Annual Joint Workshop
- 2024-
- The 2024 ASA-NJ chapter/Bayer Annual Joint Workshop
- Kymriah (tisagenlecleucel) – Statistical Challenges and Innovation in the Development and Approval
- Challenges and Lessons Learned in Autologous Chimeric Antigen Receptor TCell Therapy Development from a Statistical Perspective
- Crystal Balls and Counterfactuals: Evidence Generation for Cell and Gene Therapies
- The Role of Statistical Thinking in the Review and Approval of Cellular and Gene Therapies
- Statistical Challenges Arising in the Design and Analysis of Trials of CAR T-cell Therapies
- The 2024 ASA-NJ chapter/Bayer Annual Joint Workshop